CN109419805A - 一种肺心病患者用强心剂 - Google Patents
一种肺心病患者用强心剂 Download PDFInfo
- Publication number
- CN109419805A CN109419805A CN201710717793.2A CN201710717793A CN109419805A CN 109419805 A CN109419805 A CN 109419805A CN 201710717793 A CN201710717793 A CN 201710717793A CN 109419805 A CN109419805 A CN 109419805A
- Authority
- CN
- China
- Prior art keywords
- patients
- cardiotonic
- cor pulmonale
- strophanthin
- milligram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Abstract
本发明涉及一种肺心病患者用强心剂，包括毛花苷丙、毒毛花苷和葡萄糖注射液；所述的毛花苷丙：0．2～0.4毫克；所述的毒毛花苷K:0.125毫克；所述的葡萄糖注射液20～40毫克；与生理盐水按组份配比混合静脉注射。本发明的有益效果是：治疗效果好，组份配比简单，价格低廉。
Description
技术领域
本发明涉及一种强心剂，具体的涉及一种肺心病患者用强心剂，属于药物制备类领域。
背景技术
肺源性心脏病（简称肺心病）主要是由于支气管-肺组织或肺动脉血管病变所致肺动脉高压引起的心脏病。根据起病缓急和病程长短，可分为急性和慢性两类。临床上以后者多见。本病发展缓慢，临床上除原有肺、胸疾病的各种症状和体征外，主要是逐步出现肺、心功能衰竭以及其他器官损害的征象。
目前，现有技术的治疗效果及其有限，肺心病患者由于心肌缺氧，对洋地黄的耐受性低，易引起中毒反应，出现心律失常，因此应选用作用迅速、排泄快的强心剂，攻克此类治疗难题，是本发明研究的目的所在。
发明内容
为克服现有技术不足，本发明提供一种肺心病患者用强心剂，通过各组分量的相互配合，实现了有效治疗目的。本发明治疗效果好，组份配比简单，价格低廉。
为解决现有技术问题，本发明所采用的技术方案是：
一种肺心病患者用强心剂，包括毛花苷丙、毒毛花苷和葡萄糖注射液；所述的毛花苷丙：0．2～0.4毫克；所述的毒毛花苷K:0.125毫克；所述的葡萄糖注射液20～40毫克；与生理盐水按组份配比混合静脉注射。
进一步的，所述的剂量应为常规用量的1／2～1／3。
本发明的有益效果是：治疗效果好，组份配比简单，价格低廉。
具体实施方式
为了使本领域技术人员能够更加理解本发明技术内容，下面结合实施例对本发明做进一步分析。
实施例：一种肺心病患者用强心剂，包括毛花苷丙、毒毛花苷和葡萄糖注射液；所述的毛花苷丙：0.4毫克；毒毛花苷0.125毫克；所述的葡萄糖注射液40毫克；与生理盐水按100组份配比混合静脉注射。肺心病患者由于心肌缺氧，对洋地黄的耐受性低，易引起中毒反应，出现心律失常，因此应选用作用迅速、排泄快的强心剂，剂量应为常规用量的1／2～1／3。
以上对本申请所提供的技术方案进行了详细介绍，本文中应用了实施例对本申请的原理及实施方式进行了阐述，以上实施例的说明只是用于帮助理解本申请的方法及其核心思想；同时，对于本领域的一般技术人员，依据本申请的思想，在具体实施方式及应用范围上均会有改变之处，综上所述，本说明书内容不应理解为对本申请的限制。
Claims (2)
1.一种肺心病患者用强心剂，其特征在于：包括毛花苷丙、毒毛花苷和葡萄糖注射液；所述的毛花苷丙：0．2～0.4毫克；所述的毒毛花苷K:0.125毫克；所述的葡萄糖注射液20～40毫克；与生理盐水按组份配比混合静脉注射。
2.根据权利要求1所述的一种肺心病患者用强心剂，其特征在于：所述的剂量应为常规用量的1／2～1／3。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710717793.2A CN109419805A (zh) | 2017-08-21 | 2017-08-21 | 一种肺心病患者用强心剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710717793.2A CN109419805A (zh) | 2017-08-21 | 2017-08-21 | 一种肺心病患者用强心剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109419805A true CN109419805A (zh) | 2019-03-05 |
Family
ID=65498996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710717793.2A Pending CN109419805A (zh) | 2017-08-21 | 2017-08-21 | 一种肺心病患者用强心剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109419805A (zh) |
-
2017
- 2017-08-21 CN CN201710717793.2A patent/CN109419805A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Durlach et al. | Magnesium chloride or magnesium sulfate: a genuine question | |
| Onorati et al. | Leukocyte filtration ameliorates the inflammatory response in patients with mild to moderate lung dysfunction | |
| CN105748464B (zh) | 一种治疗射血分数保留的心力衰竭的药物组合物及其应用 | |
| CN109419805A (zh) | 一种肺心病患者用强心剂 | |
| Zangrillo et al. | Esmolol in cardiac surgery: A randomized controlled trial | |
| Ebade et al. | Ascorbic acid versus magnesium for the prevention of atrial fibrillation after coronary artery bypass grafting surgery | |
| Jeon et al. | Improvement of Chronic Bleeding in the Patient with Unresectable Advanced Gastric Cancer Using the Decoction of-a Case Report | |
| PT1658879E (pt) | Radix salviae miltiorrhizae, o seu extrato e composição para o tratamento de doenças de resistência à aspirina | |
| CN108939137A (zh) | 一种复合止血粉及其制备方法 | |
| CN101530561B (zh) | 一种止血药 | |
| Allama et al. | Levosimendan vs intra-aortic balloon pump in low ejection fraction coronary artery bypass grafting patients | |
| CN1299676C (zh) | 一种抗缺氧药物组合物 | |
| CN106822284A (zh) | 一种治疗月经不调的药物 | |
| Jing et al. | Recombinant human endostatin-associated acute left heart failure | |
| Hastings et al. | The metabolic and endocrine response to trauma | |
| CN108066414A (zh) | 一种治疗灰指甲的药物 | |
| Merle et al. | P1334: A multicentre, randomised, open-label study comparing the efficacy and safety of two doses of Doxorubicin TransdrugTM to best standard of care in patients with advanced Hepatocellular Carcinoma (HCC) after sorafenib. The relive study | |
| Nagy | 24-HOUR AMBULATORY BLOOD PRESSURE REDUCTION WITH A PERINDOPRIL/AMLODIPINE FIXED-DOSE COMBINATION: PP. 15.427 | |
| Thomas et al. | Intravenous lipid emulsion therapy and VA-ECMO rescue therapy for massive venlafaxine and clonazepam overdose | |
| Hafner et al. | Hyperoxia in Intensive Care and Emergency Medicine: Dr. Jekyll or Mr. Hyde? An Update | |
| EP1970069A1 (en) | Medicament containing Danshen for use in prevention and/or treatment of infections | |
| CN104324267A (zh) | 治疗消化道出血的中成药 | |
| CN108653491A (zh) | 一种治疗心脑血管疾病的药 | |
| CN110638957A (zh) | 一种疏血通中药 | |
| Wong et al. | Vigorous Vascular Contraction Mimicking Myocardial Bridge Resulting from Digoxin Treatment in an Elderly Patient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190305 |